Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Regorafenib hydrochloride
Cat. No.:
OB0225LY-0363
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and LC-MS.
Size:
Product Overview
Description:
Regorafenib hydrochloride is a multi-targeted tyrosine kinase inhibitor with anti-tumor properties, mainly used to intervene in the signaling pathways of tumor cells.
Synonym:
BAY73-4506 hydrochloride; 835621-07-3; Regorafenib; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; 4-(4-(((4-Chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide
CAS No.:
835621-07-3
Compound CID:
11167602
Formula:
C21H16Cl2F4N4O3
Formula Weight:
519.28
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Regorafenib hydrochloride can be used in cancer research or play an important role in the tumor microenvironment.
Library Information
Targets:
Raf; VEGFR1; VEGFR3; VEGFR2; PDGFRβ; Kit; RET; Raf-1
Pathways:
Autophagy; MAPK; Angiogenesis; Tyrosine kinase/adaptors; Apoptosis
Plate Number:
AOCL-5
Plate Location:
f8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
40 mg/mL; 77.03 mM
